ACRS | Aclaris Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.7100 - 2.9000
52 Week Range	0.8560 - 5.17
Beta	0.10
Implied Volatility	172.85%
IV Rank	0.77%
Day's Volume	1,156,054
Average Volume	2,349,512
Shares Outstanding	71,430,900
Market Cap	194,292,048
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2015-10-06

Valuation
Profitability
Growth
Health
P/E Ratio	-5.23
Forward P/E Ratio	-4.57
EPS	-0.52
1YR Price Target	30.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	86
Country	USA
Website	ACRS

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

ACRS's peers: NEOG, QGEN, OLK, SYNH, SHC, RDNT, MYGN, GTH, BDSX, CSTL, PRE, IQV, MEDP, ICLR, CHEK, NEO, TRIB, RVTY

*Chart delayed

Analyzing fundamentals for ACRS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see ACRS Fundamentals page.

Watching at ACRS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on ACRS Technicals page.